Global Veterinary Stem Cell Therapy Market

Global Veterinary Stem Cell Therapy Market Size Insights Forecasts to 2035

• The Global Veterinary Stem Cell Therapy Market Size Was Estimated at USD 143.63 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 9.34 % from 2025 to 2035
• The Worldwide Veterinary Stem Cell Therapy Market Size is Expected to Reach USD 383.44 Million by 2035
• North America is expected to grow the fastest during the forecast period.

According to a research report published by Decisions Advisors and Consulting, The Global Veterinary Stem Cell Therapy Market Size Was Worth Around USD 143.63 Million In 2024 And Is Predicted To Grow To Around USD 383.44 Million By 2035 With A Compound Annual Growth Rate (CAGR) Of 9.34 % From 2025 To 2035. The industry has seen considerable growth as a result of the rise in chronic and degenerative conditions in pets, continued advances in stem cell therapy technology, humanisation of pets, and increased openness by pet owners to invest in new technology in the field of veterinary medicine. The market is also encouraged by a strong and rising need for advanced and disease-modifying treatments in the field of veterinary medicine. The drugs get a boost from the unique ability to address both the root causes of many chronic conditions and relieve the pet from the symptoms.

 

Market Overview

The veterinary stem cell therapy market is defined as the global market dealing with the use of stem cell therapy in animal health, such as dogs, cats, and horses. It also deals with livestock. It is the process of using stem cell therapy for the repair and regeneration of damaged tissues. It can also involve the replacement of damaged tissues. The animal stem cell therapy market is witnessing a sharp increase in the demand for advanced veterinary procedures. This is coming from a learning curve from pet owners who are embracing new technologies for curing conditions and injuries that affect their pets. This can also be related to the fact that they are becoming more knowledgeable about the benefits of stem cell therapy. It is geared towards regenerating and healing. This is a clear indication of a paradigm shift concerning effective treatment solutions for their pets. Gallant, a veterinary biotechnology company, raised $18 million in Series B funding to advance its ready-to-use stem cell therapies for pets toward FDA approval. The therapies target conditions like refractory feline chronic gingivostomatitis and could mark the first FDA-approved off-the-shelf stem cell treatment in veterinary medicine.

 

Report Coverage

This research report categorises the veterinary stem cell therapy market based on various segments and regions, forecasts revenue growth, and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the veterinary stem cell therapy market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the veterinary stem cell therapy market.     

 

Driving Factors  

The animal stem cell therapy market is growing with increasing innovation, driven by advances in veterinary medicine and growing awareness of the benefits that regenerative therapies may be able to offer. It appears that this is an expanding market due to pet owners and veterinarians alike taking hold of the effective treatment options brought about by stem cell treatments for many ailments, such as degenerative diseases and orthopaedic conditions. The increased acceptance of these treatments is almost certainly linked to ongoing studies and clinical research exhibiting safety and effectiveness. Moreover, rising pet ownership and humanisation of pets fuel the need for innovative treatment options; thus, this industry probably holds a bright future. Additionally, the animal stem cell therapy market encompasses various applications, such as companion animals and livestock. The existence of a wide range of applications serves to show the broader scope of interest taken by stakeholders, including pharmaceutical firms, research institutions, and veterinary clinics. With further maturation, there would likely be more collaboration efforts between such entities for innovation and strong enabling towards the discovery of new therapies.

 

Restraining Factors  

Factors affecting the veterinary stem cell therapy market are the high cost of therapy, insufficient scientific rationale to support the practice, regulatory issues, and the absence of standardised therapeutic protocols. Such obstacles affect the rate at which the therapy is being applied despite the growing need for sophisticated regenerative therapies.

 

Market Segmentation    

The veterinary stem cell therapy market share is classified into therapy type and application.  

  

• The autologous stem cell therapy segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.        

Based on the therapy type, the veterinary stem cell therapy market is divided into autologous stem cell therapy, allogenic stem cell therapy, and induced pluripotent stem cell therapy. Among these, the autologous stem cell therapy segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. This is primarily due to primarily because of its safety profile. This is because this new therapy uses stem cells found in the animal's body and therefore minimises rejection. This therapy is effective in treating various conditions, especially orthopaedic injuries like arthritis and tendon injuries.

 

• The orthopaedic conditions segment accounted for the highest market revenue in 2024 and is anticipated to grow at a significant CAGR during the forecast period.      

Based on the application, the veterinary stem cell therapy market is divided into orthopaedic conditions, skin disorders, cardiovascular diseases, and neurological disorders. Among these, the orthopaedic conditions segment accounted for the highest market revenue in 2024 and is anticipated to grow at a significant CAGR during the forecast period. Their efficient management of joint diseases, injuries, and degenerative conditions, which are common among various animal species. The success of stem cells in hastening the healing and mobility recovery further establishes their usefulness.

Regional Segment Analysis of the Veterinary Stem Cell Therapy Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

Asia Pacific is anticipated to hold the largest share of the veterinary stem cell therapy market over the predicted timeframe.     

Asia Pacific is anticipated to hold the largest share of the veterinary stem cell therapy market over the predicted timeframe. Factors driving the growth of this industry include a rise in the number of pets, a rise in living standards, and an increased awareness of advanced facilities in pet healthcare. The countries that lead the way in this industry are China and Australia, which provide a favourable atmosphere for the development of this sector, as the government regulations encourage the development of advanced facilities in pet healthcare through techniques such as stem cell therapy methods for pets.

 

India opened its first Animal Stem Cell Biobank in Hyderabad, aimed at driving regenerative medicine and boosting livestock health and productivity. This facility is expected to support veterinary research, improve disease management, and enhance agricultural sustainability.

 

North America is expected to grow at a rapid CAGR in the veterinary stem cell therapy market during the forecast period. North America dominates the market for animal stem cell therapy, with a 60% share of the total market. The growth of this market is driven by various factors, including an increase in pet ownership, advances in veterinary care, and a conducive regulatory environment. The demand for new treatments for chronic diseases, especially for pets, is another major driver for this market. Organisations such as the FDA play a vital role in regulating this therapy, thus promoting its use. The country leading this market is the US, and its major contributors are VetStem Inc. and Aratana Therapeutics. The second country that contributes to this market is Canada, and its contributor is StemCell Technologies.

 

The FDA approved Cornell University’s clinical trials to test stem cell therapies in dogs and horses, focusing on musculoskeletal and neurological conditions such as osteoarthritis, tendinopathy, and hip/elbow dysplasia. This marks a major step forward in veterinary regenerative medicine.

 

Competitive Analysis:   

The report offers the appropriate analysis of the key organisations/companies involved within the veterinary stem cell therapy market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.  

 

List of Key Companies

• Aratana Therapeutics
• Ardent
• Boehringer Ingelheim International GmbH
• eQcell Inc
• Gallant
• Kintor Pharmaceutical Limited
• Magellan Stem Cells
• MediVet Biologics
• Medrego
• Regeneus Ltd (AU)
• StemcellX
• Vetbiologics
• Vetherapy
• Vetstem, Inc.
• Others  

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs) 

 

Recent Development

 

• In October 2025, Thailand launched its first pet stem cell bank through a partnership between PetGeneX and the National Innovation Agency (NIA), marking a breakthrough in veterinary healthcare and pet longevity. The initiative reflects the country’s growing “pet parenting” trend and rising demand for advanced medical innovation.  

 

Market Segment  

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Decisions Advisors has segmented the veterinary stem cell therapy market based on the below-mentioned segments: 

  

Global Veterinary Stem Cell Therapy Market, By Therapy Type

• Autologous Stem Cell Therapy
• Allogenic Stem Cell Therapy
• Induced Pluripotent Stem Cell Therapy

 

Global Veterinary Stem Cell Therapy Market, By Application

• Orthopaedic Conditions
• Skin Disorders
• Cardiovascular Diseases
• Neurological Disorders

 

Global Veterinary Stem Cell Therapy Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa

 

Frequently Asked Questions (FAQ)

 

1. What is the projected size and growth rate of the global veterinary stem cell therapy market?

The market was valued at USD 143.63 million in 2024 and is expected to reach USD 383.44 million by 2035, growing at a CAGR of 9.34% from 2025 to 2035.

 

2. Which therapy type dominates the market, and why?

Autologous stem cell therapy held the largest share in 2024 and is projected to grow at a significant CAGR. Its popularity stems from a strong safety profile, as it uses the animal's own stem cells, minimising rejection risks—making it ideal for orthopaedic injuries like arthritis.

 

3. What is the leading application segment in this market?

Orthopaedic conditions generated the highest revenue in 2024 and are expected to maintain strong growth. Stem cells excel here by promoting healing and mobility recovery in joint diseases, injuries, and degenerative issues common in pets and livestock.

 

4. Which region holds the largest market share, and which is growing fastest?

Asia Pacific is anticipated to hold the largest share over the forecast period, driven by rising pet ownership, higher living standards, and supportive regulations in countries like China, India, and Australia. North America, however, is expected to grow at the fastest CAGR, fueled by high pet ownership (60% market share) and FDA-backed advancements.

 

5. What are the main drivers behind market growth?

Key factors include rising chronic/degenerative conditions in pets, advances in stem cell technology, pet humanisation (leading owners to invest in innovative treatments), and demand for regenerative therapies that target root causes in companion animals and livestock.

 

6. What challenges or restraining factors impact the market?

High therapy costs, lack of robust scientific evidence, regulatory hurdles, and absence of standardised protocols slow adoption, despite growing demand for advanced veterinary solutions.

 

7. Who are some key players in the veterinary stem cell therapy market?

Major companies include Vetstem Inc., Gallant, MediVet Biologics, Aratana Therapeutics, Boehringer Ingelheim, eQcell Inc., Regeneus Ltd, and StemCellX, with recent developments like Gallant's $18M funding for FDA-approvable pet therapies and India's first Animal Stem Cell Biobank.